REMEGEN CO. LTD YC 1 (REG) - Net Assets
Based on the latest financial reports, REMEGEN CO. LTD YC 1 (REG) has net assets worth €3.61 Billion EUR (≈ $4.22 Billion USD) as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€7.25 Billion ≈ $8.47 Billion USD) and total liabilities (€3.64 Billion ≈ $4.25 Billion USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check REMEGEN CO. LTD YC 1 liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €3.61 Billion |
| % of Total Assets | 49.79% |
| Annual Growth Rate | 1.16% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 51.71 |
REMEGEN CO. LTD YC 1 - Net Assets Trend (2021–2025)
This chart illustrates how REMEGEN CO. LTD YC 1's net assets have evolved over time, based on quarterly financial data. Also explore REG asset base for the complete picture of this company's asset base.
Annual Net Assets for REMEGEN CO. LTD YC 1 (2021–2025)
The table below shows the annual net assets of REMEGEN CO. LTD YC 1 from 2021 to 2025. For live valuation and market cap data, see REMEGEN CO. LTD YC 1 market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | €3.61 Billion ≈ $4.22 Billion |
+81.69% |
| 2024-12-31 | €1.99 Billion ≈ $2.32 Billion |
-42.22% |
| 2023-12-31 | €3.44 Billion ≈ $4.02 Billion |
-30.98% |
| 2022-12-31 | €4.98 Billion ≈ $5.82 Billion |
+44.51% |
| 2021-12-31 | €3.45 Billion ≈ $4.03 Billion |
-- |
Equity Component Analysis
This analysis shows how different components contribute to REMEGEN CO. LTD YC 1's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 360671600000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | €7.22 Billion | 199.94% |
| Total Equity | €3.61 Billion | 100.00% |
REMEGEN CO. LTD YC 1 Competitors by Market Cap
The table below lists competitors of REMEGEN CO. LTD YC 1 ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Teekay Tankers Ltd
NYSE:TNK
|
$2.31 Billion |
|
Inv La Constru
SN:ILC
|
$2.31 Billion |
|
Nektar Therapeutics
NASDAQ:NKTR
|
$2.31 Billion |
|
Energisa S.A
SA:ENGI3
|
$2.32 Billion |
|
Pandox AB (publ)
ST:PNDX-B
|
$2.31 Billion |
|
Shenzhen Expressway Co Ltd
SHG:600548
|
$2.31 Billion |
|
Weifu High-Technology Group Co Ltd
SHE:000581
|
$2.31 Billion |
|
Sino-Platinum Metals Co Ltd
SHG:600459
|
$2.31 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in REMEGEN CO. LTD YC 1's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 1,986,201,000 to 3,608,822,000, a change of 1,622,621,000 (81.7%).
- Net income of 709,650,000 contributed positively to equity growth.
- New share issuances of 820,921,000 increased equity.
- Other factors increased equity by 92,050,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €709.65 Million | +19.66% |
| Share Issuances | €820.92 Million | +22.75% |
| Other Changes | €92.05 Million | +2.55% |
| Total Change | €- | 81.69% |
Book Value vs Market Value Analysis
This analysis compares REMEGEN CO. LTD YC 1's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.48x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has increased from 1.35x to 1.48x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2021-12-31 | €7.04 | €9.48 | x |
| 2022-12-31 | €9.15 | €9.48 | x |
| 2023-12-31 | €6.32 | €9.48 | x |
| 2024-12-31 | €3.65 | €9.48 | x |
| 2025-12-31 | €6.40 | €9.48 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently REMEGEN CO. LTD YC 1 utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 19.66%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 21.89%
- • Asset Turnover: 0.45x
- • Equity Multiplier: 2.01x
- Recent ROE (19.66%) is above the historical average (-22.05%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2021 | 8.02% | 19.40% | 0.34x | 1.21x | €-68.38 Million |
| 2022 | -20.06% | -130.09% | 0.13x | 1.21x | €-1.50 Billion |
| 2023 | -43.97% | -140.43% | 0.19x | 1.61x | €-1.85 Billion |
| 2024 | -73.93% | -85.86% | 0.31x | 2.77x | €-1.67 Billion |
| 2025 | 19.66% | 21.89% | 0.45x | 2.01x | €348.77 Million |
Industry Comparison
This section compares REMEGEN CO. LTD YC 1's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $429,291,566
- Average return on equity (ROE) among peers: -57.45%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| REMEGEN CO. LTD YC 1 (REG) | €3.61 Billion | 8.02% | 1.01x | $2.31 Billion |
| PROQR THERAPEUTICS EO-04 (0PQ) | $41.39 Million | -67.94% | 2.33x | $142.34 Million |
| TIZIANA LIFE SCIENCES LTD (0RP) | $3.94 Million | -301.40% | 1.87x | $161.62 Million |
| Theravance Biopharma Inc (0TB) | $-51.59 Million | 0.00% | 0.00x | $828.57 Million |
| I-MAB SPONS.ADS/1 -0001 (0VY) | $421.77 Million | -87.98% | 0.40x | $202.81 Million |
| PreveCeutical Medical Inc (18H) | $-4.49 Million | 0.00% | 0.00x | $3.34 Million |
| Argen-X (1AE) | $2.53 Billion | -16.11% | 0.12x | $41.67 Billion |
| WAVE LIFE SCIENCES LTD. (1U5) | $518.36 Million | -39.43% | 0.23x | $1.14 Billion |
| BIOCURE TECHNOLOGY INC. (1WH) | $1.34 Million | -19.58% | 0.49x | $960.84K |
| ZAI LAB LTD0000006 (1ZLB) | $796.12 Million | -42.03% | 0.30x | $1.82 Billion |
| BioNTech SE (22UA) | $31.86 Million | 0.00% | 11.24x | $20.05 Billion |
About REMEGEN CO. LTD YC 1
RemeGen Co., Ltd., a biopharmaceutical company, discovers, develops, produces, and commercializes biological drugs for the treatment of autoimmune, oncology, and ophthalmic diseases in Mainland China and the United States. The company offers Telitacicept (RC18) for the treatment of systemic lupus erythematosus (SLE) autoimmune disease, rheumatoid arthritis, and myasthenia gravis; and Disitamab Ve… Read more